Acepodia® is advancing drug discovery with conjugation technologies in cell Therapy and ADC
We are transforming cancer treatment with first-in-class immune cell engagers, with enhanced and targeted potency via Antibody-Cell Conjugation (ACC™) technology, improved safety and broad applicability across hematologic and solid tumor cancers. ACC™ platform technology is a family of Click Chemistry From Nobel Prize laureate-Bertozzi’s Lab.
Acepodia® is a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC™) platform technology to address gaps in cancer care.
ACC™, is inherited from Professor Carolyn Bertozzi's pioneering work in the development of biorthogonal chemistry which moves click chemistry into living organisms. And she won the Nobel Prize for Chemistry in 2022.
ACC™ uses this live-cell compatible chemistry to attach tumor-targeting antibodies directly to variety receptors of immune cells enhancing the lock between immune and cancer cells that to generate highly specific, potent cell therapies and can significantly enhance the potency of immune cells, without the need for genetic engineering.
Acepodia’s gamma delta (γδ)2 T cell program harnesses the unique properties of γδ2 T cells to develop a new class of off-the-shelf allogeneic cell therapies for the treatment of cancer. γδ2 T cells have characteristics of both the innate and adaptive immune systems that make them an ideal chassis for the development of cell therapies. This cell type can recognize and attack cancerous cells as well as coordinate a broad antitumor immune response by recruiting other immune factors and cells to the site of disease. γδ2 T cells have also been shown to preferentially traffic to distinct tissues and could be ideally suited for more targeted treatment of certain types of cancers.
Acepodia’s Antibody-Dual-Drugs Conjugation (AD2C™) platform which easily plug-and-plays multiple types of linker-payloads through site-specific conjugation process without compromising conjugation efficiency and casting minimal impact on antibody binding capacity. This platform has potential to increase the targeted delivery with improved efficacy.
ADVANCING THE NEXT GENERATION OF IMMUNOTHERAPY
GlobeNewswire
